查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1860000

白蛋白（作為賦形劑）：全球市場佔有率和排名、總收入和需求預測（2025-2031 年）

Albumin (as Excipient) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 122 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球白蛋白（作為賦形劑）市場規模估計為 15.94 億美元，預計到 2031 年將達到 24.54 億美元，在預測期（2025-2031 年）內以 6.5% 的複合年成長率成長。

本報告對近期白蛋白（作為賦形劑）關稅調整和國際戰略反制措施的跨境產業佈局、資本配置模式、區域經濟相互依存關係和供應鏈重組進行了全面評估。

白蛋白輔料是指用作生物製藥輔料的人血清白蛋白（HSA）或重組人血清白蛋白（rHSA）。其主要功能包括穩定蛋白質藥物的結構和活性，作為載體提高藥物的溶解度和生物利用度，以及作為疫苗和細胞培養基的營養成分。隨著生物製藥和疫苗研發的進步，白蛋白輔料在藥物製劑中的應用日益廣泛。 2024年，全球白蛋白（作為輔料）產量預計將達到約440萬噸，全球平均市場價格約為每公斤3,622美元。

由於全球慢性病發病率上升、生物製藥行業快速發展以及對高效藥物遞送系統的需求不斷成長，白蛋白輔料市場正經歷前所未有的成長機會。白蛋白輔料具有優異的生物相容性和穩定性，是疫苗研發和基因治療等領域不可或缺的成分。此外，重組白蛋白技術的進步使生產過程更加安全可控，進一步推動了市場成長。

儘管前景光明，白蛋白輔料市場仍面臨諸多挑戰。首先，原料的採購和品管至關重要，尤其是人類血清白蛋白的供應，會直接影響生產的穩定性。其次，嚴格的監管要求和品質標準使得研發過程複雜且耗時。此外，來自新興企業和新技術的日益激烈的市場競爭，也可能威脅現有公司的市場佔有率。

下游需求主要集中在疫苗、細胞培養基、蛋白質藥物和基因治療等領域。隨著個人化醫療和精準醫療的興起，對高品質輔料的需求持續成長。此外，全球人口老化推動了慢性病治療藥物的需求，也增加了對白蛋白輔料的需求。

白蛋白輔料的主要原料包括人類血清白蛋白和重組牛血清白蛋白。人類血清白蛋白主要來自於血漿採集，但其供應受限於捐血數量以及血漿採集相關的倫理問題。同時，重組牛血清白蛋白的生產依賴生物反應器技術，增加了生產成本和技術要求。因此，穩定的原料供應和成本控制是影響白蛋白輔料市場發展的關鍵因素。

本報告旨在按地區/國家、類型和應用對全球白蛋白（作為賦形劑）市場進行全面分析，重點關注總銷售量、收入、價格、市場佔有率和主要企業的排名。

本報告以銷售量（噸）和收入（百萬美元）為單位，對白蛋白（作為輔料）的市場規模、估算和預測進行了呈現，以2024年為基準年，並涵蓋了2020年至2031年的歷史數據和預測數據。定量和定性分析將幫助讀者制定白蛋白（作為輔料）的業務和成長策略，評估市場競爭，分析自身在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • CSL
  • Grifols
  • Takeda
  • Octapharma
  • Hualan Bio
  • CBPO
  • Shanghai RAAS
  • Kedrion
  • LFB Group
  • Tiantan Bio
  • Pailin Bio
  • Boya Bio
  • Yuanda Shuyang
  • Weiguang Bio

按類型分類的細分市場

  • 濃度20-25%
  • 5%濃度

應用領域

  • 細胞培養基
  • 醫用輔料

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Albumin (as Excipient) was estimated to be worth US$ 1594 million in 2024 and is forecast to a readjusted size of US$ 2454 million by 2031 with a CAGR of 6.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Albumin (as Excipient) cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Albumin excipients refer to human serum albumin (HSA) or recombinant human serum albumin (rHSA) used as excipients in biopharmaceuticals. Their primary functions include stabilizing the structure and activity of protein drugs, enhancing drug solubility and bioavailability as carriers, and serving as nutritional components in vaccines and cell culture media. With the advancement of biologics and vaccine development, the application of albumin excipients in drug formulations is becoming increasingly widespread.In 2024, global Albumin (as Excipient) production reached approximately 440 mt, with an average global market price of around US$ 3622 per kg.

The albumin excipient market is experiencing unprecedented growth opportunities due to the global rise in chronic diseases, rapid expansion of the biopharmaceutical industry, and increasing demand for efficient drug delivery systems. Particularly in vaccine development and gene therapy, albumin excipients have become indispensable components due to their excellent biocompatibility and stability. Furthermore, advancements in recombinant albumin technologies have made the production process safer and more controllable, further driving market growth.

Despite the promising prospects, the albumin excipient market faces several challenges. Firstly, the source and quality control of raw materials are critical, especially the supply of human-derived albumin, which may affect production stability. Secondly, stringent regulatory requirements and quality standards make the research and development process complex and time-consuming. Additionally, increasing market competition from emerging enterprises and technologies may threaten the market share of existing companies.

Downstream demand is primarily concentrated in areas such as vaccines, cell culture media, protein drugs, and gene therapies. With the rise of personalized medicine and precision therapy, the demand for high-quality excipients continues to increase. Moreover, the growing aging population globally is driving the demand for chronic disease treatment drugs, thereby boosting the need for albumin excipients.

The main raw materials for albumin excipients include human serum albumin and recombinant bovine serum albumin. Human serum albumin is primarily sourced from plasma collection; however, its supply is limited by the number of blood donors and ethical issues related to plasma collection. On the other hand, recombinant bovine serum albumin production relies on bioreactor technology, which has higher production costs and technical requirements. Therefore, the stable supply and cost control of raw materials are key factors influencing the development of the albumin excipient market.

This report aims to provide a comprehensive presentation of the global market for Albumin (as Excipient), focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Albumin (as Excipient) by region & country, by Type, and by Application.

The Albumin (as Excipient) market size, estimations, and forecasts are provided in terms of sales volume (MT) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Albumin (as Excipient).

Market Segmentation

By Company

  • CSL
  • Grifols
  • Takeda
  • Octapharma
  • Hualan Bio
  • CBPO
  • Shanghai RAAS
  • Kedrion
  • LFB Group
  • Tiantan Bio
  • Pailin Bio
  • Boya Bio
  • Yuanda Shuyang
  • Weiguang Bio

Segment by Type

  • 20-25% Concentrations
  • 5% Concentrations

Segment by Application

  • Cell Culture Media
  • Medical Excipient

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Albumin (as Excipient) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Albumin (as Excipient) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Albumin (as Excipient) in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Albumin (as Excipient) Product Introduction
  • 1.2 Global Albumin (as Excipient) Market Size Forecast
    • 1.2.1 Global Albumin (as Excipient) Sales Value (2020-2031)
    • 1.2.2 Global Albumin (as Excipient) Sales Volume (2020-2031)
    • 1.2.3 Global Albumin (as Excipient) Sales Price (2020-2031)
  • 1.3 Albumin (as Excipient) Market Trends & Drivers
    • 1.3.1 Albumin (as Excipient) Industry Trends
    • 1.3.2 Albumin (as Excipient) Market Drivers & Opportunity
    • 1.3.3 Albumin (as Excipient) Market Challenges
    • 1.3.4 Albumin (as Excipient) Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Albumin (as Excipient) Players Revenue Ranking (2024)
  • 2.2 Global Albumin (as Excipient) Revenue by Company (2020-2025)
  • 2.3 Global Albumin (as Excipient) Players Sales Volume Ranking (2024)
  • 2.4 Global Albumin (as Excipient) Sales Volume by Company Players (2020-2025)
  • 2.5 Global Albumin (as Excipient) Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Albumin (as Excipient) Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Albumin (as Excipient) Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Albumin (as Excipient)
  • 2.9 Albumin (as Excipient) Market Competitive Analysis
    • 2.9.1 Albumin (as Excipient) Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Albumin (as Excipient) Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Albumin (as Excipient) as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 20-25% Concentrations
    • 3.1.2 5% Concentrations
  • 3.2 Global Albumin (as Excipient) Sales Value by Type
    • 3.2.1 Global Albumin (as Excipient) Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Albumin (as Excipient) Sales Value, by Type (2020-2031)
    • 3.2.3 Global Albumin (as Excipient) Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Albumin (as Excipient) Sales Volume by Type
    • 3.3.1 Global Albumin (as Excipient) Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Albumin (as Excipient) Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Albumin (as Excipient) Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Albumin (as Excipient) Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Cell Culture Media
    • 4.1.2 Medical Excipient
  • 4.2 Global Albumin (as Excipient) Sales Value by Application
    • 4.2.1 Global Albumin (as Excipient) Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Albumin (as Excipient) Sales Value, by Application (2020-2031)
    • 4.2.3 Global Albumin (as Excipient) Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Albumin (as Excipient) Sales Volume by Application
    • 4.3.1 Global Albumin (as Excipient) Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Albumin (as Excipient) Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Albumin (as Excipient) Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Albumin (as Excipient) Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Albumin (as Excipient) Sales Value by Region
    • 5.1.1 Global Albumin (as Excipient) Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Albumin (as Excipient) Sales Value by Region (2020-2025)
    • 5.1.3 Global Albumin (as Excipient) Sales Value by Region (2026-2031)
    • 5.1.4 Global Albumin (as Excipient) Sales Value by Region (%), (2020-2031)
  • 5.2 Global Albumin (as Excipient) Sales Volume by Region
    • 5.2.1 Global Albumin (as Excipient) Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Albumin (as Excipient) Sales Volume by Region (2020-2025)
    • 5.2.3 Global Albumin (as Excipient) Sales Volume by Region (2026-2031)
    • 5.2.4 Global Albumin (as Excipient) Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Albumin (as Excipient) Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Albumin (as Excipient) Sales Value, 2020-2031
    • 5.4.2 North America Albumin (as Excipient) Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Albumin (as Excipient) Sales Value, 2020-2031
    • 5.5.2 Europe Albumin (as Excipient) Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Albumin (as Excipient) Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Albumin (as Excipient) Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Albumin (as Excipient) Sales Value, 2020-2031
    • 5.7.2 South America Albumin (as Excipient) Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Albumin (as Excipient) Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Albumin (as Excipient) Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Albumin (as Excipient) Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Albumin (as Excipient) Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Albumin (as Excipient) Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Albumin (as Excipient) Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Albumin (as Excipient) Sales Value, 2020-2031
    • 6.3.2 United States Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Albumin (as Excipient) Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Albumin (as Excipient) Sales Value, 2020-2031
    • 6.4.2 Europe Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Albumin (as Excipient) Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Albumin (as Excipient) Sales Value, 2020-2031
    • 6.5.2 China Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Albumin (as Excipient) Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Albumin (as Excipient) Sales Value, 2020-2031
    • 6.6.2 Japan Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Albumin (as Excipient) Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Albumin (as Excipient) Sales Value, 2020-2031
    • 6.7.2 South Korea Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Albumin (as Excipient) Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Albumin (as Excipient) Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Albumin (as Excipient) Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Albumin (as Excipient) Sales Value, 2020-2031
    • 6.9.2 India Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Albumin (as Excipient) Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 CSL
    • 7.1.1 CSL Company Information
    • 7.1.2 CSL Introduction and Business Overview
    • 7.1.3 CSL Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 CSL Albumin (as Excipient) Product Offerings
    • 7.1.5 CSL Recent Development
  • 7.2 Grifols
    • 7.2.1 Grifols Company Information
    • 7.2.2 Grifols Introduction and Business Overview
    • 7.2.3 Grifols Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Grifols Albumin (as Excipient) Product Offerings
    • 7.2.5 Grifols Recent Development
  • 7.3 Takeda
    • 7.3.1 Takeda Company Information
    • 7.3.2 Takeda Introduction and Business Overview
    • 7.3.3 Takeda Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Takeda Albumin (as Excipient) Product Offerings
    • 7.3.5 Takeda Recent Development
  • 7.4 Octapharma
    • 7.4.1 Octapharma Company Information
    • 7.4.2 Octapharma Introduction and Business Overview
    • 7.4.3 Octapharma Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Octapharma Albumin (as Excipient) Product Offerings
    • 7.4.5 Octapharma Recent Development
  • 7.5 Hualan Bio
    • 7.5.1 Hualan Bio Company Information
    • 7.5.2 Hualan Bio Introduction and Business Overview
    • 7.5.3 Hualan Bio Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Hualan Bio Albumin (as Excipient) Product Offerings
    • 7.5.5 Hualan Bio Recent Development
  • 7.6 CBPO
    • 7.6.1 CBPO Company Information
    • 7.6.2 CBPO Introduction and Business Overview
    • 7.6.3 CBPO Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 CBPO Albumin (as Excipient) Product Offerings
    • 7.6.5 CBPO Recent Development
  • 7.7 Shanghai RAAS
    • 7.7.1 Shanghai RAAS Company Information
    • 7.7.2 Shanghai RAAS Introduction and Business Overview
    • 7.7.3 Shanghai RAAS Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Shanghai RAAS Albumin (as Excipient) Product Offerings
    • 7.7.5 Shanghai RAAS Recent Development
  • 7.8 Kedrion
    • 7.8.1 Kedrion Company Information
    • 7.8.2 Kedrion Introduction and Business Overview
    • 7.8.3 Kedrion Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Kedrion Albumin (as Excipient) Product Offerings
    • 7.8.5 Kedrion Recent Development
  • 7.9 LFB Group
    • 7.9.1 LFB Group Company Information
    • 7.9.2 LFB Group Introduction and Business Overview
    • 7.9.3 LFB Group Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 LFB Group Albumin (as Excipient) Product Offerings
    • 7.9.5 LFB Group Recent Development
  • 7.10 Tiantan Bio
    • 7.10.1 Tiantan Bio Company Information
    • 7.10.2 Tiantan Bio Introduction and Business Overview
    • 7.10.3 Tiantan Bio Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.10.4 Tiantan Bio Albumin (as Excipient) Product Offerings
    • 7.10.5 Tiantan Bio Recent Development
  • 7.11 Pailin Bio
    • 7.11.1 Pailin Bio Company Information
    • 7.11.2 Pailin Bio Introduction and Business Overview
    • 7.11.3 Pailin Bio Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.11.4 Pailin Bio Albumin (as Excipient) Product Offerings
    • 7.11.5 Pailin Bio Recent Development
  • 7.12 Boya Bio
    • 7.12.1 Boya Bio Company Information
    • 7.12.2 Boya Bio Introduction and Business Overview
    • 7.12.3 Boya Bio Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.12.4 Boya Bio Albumin (as Excipient) Product Offerings
    • 7.12.5 Boya Bio Recent Development
  • 7.13 Yuanda Shuyang
    • 7.13.1 Yuanda Shuyang Company Information
    • 7.13.2 Yuanda Shuyang Introduction and Business Overview
    • 7.13.3 Yuanda Shuyang Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.13.4 Yuanda Shuyang Albumin (as Excipient) Product Offerings
    • 7.13.5 Yuanda Shuyang Recent Development
  • 7.14 Weiguang Bio
    • 7.14.1 Weiguang Bio Company Information
    • 7.14.2 Weiguang Bio Introduction and Business Overview
    • 7.14.3 Weiguang Bio Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.14.4 Weiguang Bio Albumin (as Excipient) Product Offerings
    • 7.14.5 Weiguang Bio Recent Development

8 Industry Chain Analysis

  • 8.1 Albumin (as Excipient) Industrial Chain
  • 8.2 Albumin (as Excipient) Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Albumin (as Excipient) Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Albumin (as Excipient) Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Albumin (as Excipient) Market Trends
  • Table 2. Albumin (as Excipient) Market Drivers & Opportunity
  • Table 3. Albumin (as Excipient) Market Challenges
  • Table 4. Albumin (as Excipient) Market Restraints
  • Table 5. Global Albumin (as Excipient) Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Albumin (as Excipient) Revenue Market Share by Company (2020-2025)
  • Table 7. Global Albumin (as Excipient) Sales Volume by Company (2020-2025) & (MT)
  • Table 8. Global Albumin (as Excipient) Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Albumin (as Excipient) Price by Company (2020-2025) & (USD/Kg)
  • Table 10. Key Manufacturers Albumin (as Excipient) Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Albumin (as Excipient) Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Albumin (as Excipient)
  • Table 13. Global Albumin (as Excipient) Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Albumin (as Excipient) as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Albumin (as Excipient) Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Albumin (as Excipient) Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Albumin (as Excipient) Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Albumin (as Excipient) Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Albumin (as Excipient) Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Albumin (as Excipient) Sales Volume by Type: 2020 VS 2024 VS 2031 (MT)
  • Table 22. Global Albumin (as Excipient) Sales Volume by Type (2020-2025) & (MT)
  • Table 23. Global Albumin (as Excipient) Sales Volume by Type (2026-2031) & (MT)
  • Table 24. Global Albumin (as Excipient) Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Albumin (as Excipient) Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Albumin (as Excipient) Price by Type (2020-2025) & (USD/Kg)
  • Table 27. Global Albumin (as Excipient) Price by Type (2026-2031) & (USD/Kg)
  • Table 28. Global Albumin (as Excipient) Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Albumin (as Excipient) Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Albumin (as Excipient) Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Albumin (as Excipient) Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Albumin (as Excipient) Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Albumin (as Excipient) Sales Volume by Application: 2020 VS 2024 VS 2031 (MT)
  • Table 34. Global Albumin (as Excipient) Sales Volume by Application (2020-2025) & (MT)
  • Table 35. Global Albumin (as Excipient) Sales Volume by Application (2026-2031) & (MT)
  • Table 36. Global Albumin (as Excipient) Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Albumin (as Excipient) Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Albumin (as Excipient) Price by Application (2020-2025) & (USD/Kg)
  • Table 39. Global Albumin (as Excipient) Price by Application (2026-2031) & (USD/Kg)
  • Table 40. Global Albumin (as Excipient) Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Albumin (as Excipient) Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Albumin (as Excipient) Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Albumin (as Excipient) Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Albumin (as Excipient) Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Albumin (as Excipient) Sales Volume by Region (MT): 2020 VS 2024 VS 2031
  • Table 46. Global Albumin (as Excipient) Sales Volume by Region (2020-2025) & (MT)
  • Table 47. Global Albumin (as Excipient) Sales Volume by Region (2026-2031) & (MT)
  • Table 48. Global Albumin (as Excipient) Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Albumin (as Excipient) Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Albumin (as Excipient) Average Price by Region (2020-2025) & (USD/Kg)
  • Table 51. Global Albumin (as Excipient) Average Price by Region (2026-2031) & (USD/Kg)
  • Table 52. Key Countries/Regions Albumin (as Excipient) Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Albumin (as Excipient) Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Albumin (as Excipient) Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Albumin (as Excipient) Sales Volume, (2020-2025) & (MT)
  • Table 56. Key Countries/Regions Albumin (as Excipient) Sales Volume, (2026-2031) & (MT)
  • Table 57. CSL Company Information
  • Table 58. CSL Introduction and Business Overview
  • Table 59. CSL Albumin (as Excipient) Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 60. CSL Albumin (as Excipient) Product Offerings
  • Table 61. CSL Recent Development
  • Table 62. Grifols Company Information
  • Table 63. Grifols Introduction and Business Overview
  • Table 64. Grifols Albumin (as Excipient) Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 65. Grifols Albumin (as Excipient) Product Offerings
  • Table 66. Grifols Recent Development
  • Table 67. Takeda Company Information
  • Table 68. Takeda Introduction and Business Overview
  • Table 69. Takeda Albumin (as Excipient) Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 70. Takeda Albumin (as Excipient) Product Offerings
  • Table 71. Takeda Recent Development
  • Table 72. Octapharma Company Information
  • Table 73. Octapharma Introduction and Business Overview
  • Table 74. Octapharma Albumin (as Excipient) Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 75. Octapharma Albumin (as Excipient) Product Offerings
  • Table 76. Octapharma Recent Development
  • Table 77. Hualan Bio Company Information
  • Table 78. Hualan Bio Introduction and Business Overview
  • Table 79. Hualan Bio Albumin (as Excipient) Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 80. Hualan Bio Albumin (as Excipient) Product Offerings
  • Table 81. Hualan Bio Recent Development
  • Table 82. CBPO Company Information
  • Table 83. CBPO Introduction and Business Overview
  • Table 84. CBPO Albumin (as Excipient) Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 85. CBPO Albumin (as Excipient) Product Offerings
  • Table 86. CBPO Recent Development
  • Table 87. Shanghai RAAS Company Information
  • Table 88. Shanghai RAAS Introduction and Business Overview
  • Table 89. Shanghai RAAS Albumin (as Excipient) Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 90. Shanghai RAAS Albumin (as Excipient) Product Offerings
  • Table 91. Shanghai RAAS Recent Development
  • Table 92. Kedrion Company Information
  • Table 93. Kedrion Introduction and Business Overview
  • Table 94. Kedrion Albumin (as Excipient) Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 95. Kedrion Albumin (as Excipient) Product Offerings
  • Table 96. Kedrion Recent Development
  • Table 97. LFB Group Company Information
  • Table 98. LFB Group Introduction and Business Overview
  • Table 99. LFB Group Albumin (as Excipient) Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 100. LFB Group Albumin (as Excipient) Product Offerings
  • Table 101. LFB Group Recent Development
  • Table 102. Tiantan Bio Company Information
  • Table 103. Tiantan Bio Introduction and Business Overview
  • Table 104. Tiantan Bio Albumin (as Excipient) Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 105. Tiantan Bio Albumin (as Excipient) Product Offerings
  • Table 106. Tiantan Bio Recent Development
  • Table 107. Pailin Bio Company Information
  • Table 108. Pailin Bio Introduction and Business Overview
  • Table 109. Pailin Bio Albumin (as Excipient) Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 110. Pailin Bio Albumin (as Excipient) Product Offerings
  • Table 111. Pailin Bio Recent Development
  • Table 112. Boya Bio Company Information
  • Table 113. Boya Bio Introduction and Business Overview
  • Table 114. Boya Bio Albumin (as Excipient) Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 115. Boya Bio Albumin (as Excipient) Product Offerings
  • Table 116. Boya Bio Recent Development
  • Table 117. Yuanda Shuyang Company Information
  • Table 118. Yuanda Shuyang Introduction and Business Overview
  • Table 119. Yuanda Shuyang Albumin (as Excipient) Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 120. Yuanda Shuyang Albumin (as Excipient) Product Offerings
  • Table 121. Yuanda Shuyang Recent Development
  • Table 122. Weiguang Bio Company Information
  • Table 123. Weiguang Bio Introduction and Business Overview
  • Table 124. Weiguang Bio Albumin (as Excipient) Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 125. Weiguang Bio Albumin (as Excipient) Product Offerings
  • Table 126. Weiguang Bio Recent Development
  • Table 127. Key Raw Materials Lists
  • Table 128. Raw Materials Key Suppliers Lists
  • Table 129. Albumin (as Excipient) Downstream Customers
  • Table 130. Albumin (as Excipient) Distributors List
  • Table 131. Research Programs/Design for This Report
  • Table 132. Key Data Information from Secondary Sources
  • Table 133. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Albumin (as Excipient) Product Picture
  • Figure 2. Global Albumin (as Excipient) Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Albumin (as Excipient) Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Albumin (as Excipient) Sales Volume (2020-2031) & (MT)
  • Figure 5. Global Albumin (as Excipient) Sales Price (2020-2031) & (USD/Kg)
  • Figure 6. Albumin (as Excipient) Report Years Considered
  • Figure 7. Global Albumin (as Excipient) Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Albumin (as Excipient) Players Sales Volume Ranking (2024) & (MT)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Albumin (as Excipient) Revenue in 2024
  • Figure 10. Albumin (as Excipient) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. 20-25% Concentrations Picture
  • Figure 12. 5% Concentrations Picture
  • Figure 13. Global Albumin (as Excipient) Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 14. Global Albumin (as Excipient) Sales Value Market Share by Type, 2024 & 2031
  • Figure 15. Global Albumin (as Excipient) Sales Volume by Type (2020 VS 2024 VS 2031) & (MT)
  • Figure 16. Global Albumin (as Excipient) Sales Volume Market Share by Type, 2024 & 2031
  • Figure 17. Global Albumin (as Excipient) Price by Type (2020-2031) & (USD/Kg)
  • Figure 18. Product Picture of Cell Culture Media
  • Figure 19. Product Picture of Medical Excipient
  • Figure 20. Global Albumin (as Excipient) Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 21. Global Albumin (as Excipient) Sales Value Market Share by Application, 2024 & 2031
  • Figure 22. Global Albumin (as Excipient) Sales Volume by Application (2020 VS 2024 VS 2031) & (MT)
  • Figure 23. Global Albumin (as Excipient) Sales Volume Market Share by Application, 2024 & 2031
  • Figure 24. Global Albumin (as Excipient) Price by Application (2020-2031) & (USD/Kg)
  • Figure 25. North America Albumin (as Excipient) Sales Value (2020-2031) & (US$ Million)
  • Figure 26. North America Albumin (as Excipient) Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Europe Albumin (as Excipient) Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. Europe Albumin (as Excipient) Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Asia Pacific Albumin (as Excipient) Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. Asia Pacific Albumin (as Excipient) Sales Value by Region (%), 2024 VS 2031
  • Figure 31. South America Albumin (as Excipient) Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. South America Albumin (as Excipient) Sales Value by Country (%), 2024 VS 2031
  • Figure 33. Middle East & Africa Albumin (as Excipient) Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. Middle East & Africa Albumin (as Excipient) Sales Value by Country (%), 2024 VS 2031
  • Figure 35. Key Countries/Regions Albumin (as Excipient) Sales Value (%), (2020-2031)
  • Figure 36. Key Countries/Regions Albumin (as Excipient) Sales Volume (%), (2020-2031)
  • Figure 37. United States Albumin (as Excipient) Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. United States Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
  • Figure 39. United States Albumin (as Excipient) Sales Value by Application (%), 2024 VS 2031
  • Figure 40. Europe Albumin (as Excipient) Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. Europe Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
  • Figure 42. Europe Albumin (as Excipient) Sales Value by Application (%), 2024 VS 2031
  • Figure 43. China Albumin (as Excipient) Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. China Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
  • Figure 45. China Albumin (as Excipient) Sales Value by Application (%), 2024 VS 2031
  • Figure 46. Japan Albumin (as Excipient) Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. Japan Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
  • Figure 48. Japan Albumin (as Excipient) Sales Value by Application (%), 2024 VS 2031
  • Figure 49. South Korea Albumin (as Excipient) Sales Value, (2020-2031) & (US$ Million)
  • Figure 50. South Korea Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
  • Figure 51. South Korea Albumin (as Excipient) Sales Value by Application (%), 2024 VS 2031
  • Figure 52. Southeast Asia Albumin (as Excipient) Sales Value, (2020-2031) & (US$ Million)
  • Figure 53. Southeast Asia Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
  • Figure 54. Southeast Asia Albumin (as Excipient) Sales Value by Application (%), 2024 VS 2031
  • Figure 55. India Albumin (as Excipient) Sales Value, (2020-2031) & (US$ Million)
  • Figure 56. India Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
  • Figure 57. India Albumin (as Excipient) Sales Value by Application (%), 2024 VS 2031
  • Figure 58. Albumin (as Excipient) Industrial Chain
  • Figure 59. Albumin (as Excipient) Manufacturing Cost Structure
  • Figure 60. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 61. Bottom-up and Top-down Approaches for This Report
  • Figure 62. Data Triangulation
  • Figure 63. Key Executives Interviewed